Literature DB >> 18239241

Predictors of high-dose antipsychotic prescription in psychiatric patients in Hong Kong.

Gabriel B K Hung1, H K Cheung.   

Abstract

OBJECTIVE: To determine the factors associated with high-dose antipsychotic prescribing for psychiatric patients in Hong Kong.
DESIGN: Retrospective cross-sectional study.
SETTING: Psychiatric in-patients and out-patients in the New Territories West Cluster, Hong Kong. PATIENTS: A total of 1129 in-patients and 7520 out-patients who received antipsychotic medications on the study date. MAIN OUTCOME MEASURES: Demographic and clinical data were compared for patients receiving 'normal' and high dosages of antipsychotic medications.
RESULTS: High dosages were prescribed for 104 (9.2%) of the in-patients and 137 (1.8%) of out-patients. Antipsychotic polypharmacy was the most powerful predictor of high-dose prescribing, with an odds ratio of 8.88 for in-patients and 10.82 for out-patients.
CONCLUSION: Antipsychotic polypharmacy was the main determinant of high-dose antipsychotic prescribing in this study. Further studies should be conducted to look for other variables contributing to such prescribing in Hong Kong.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239241

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  10 in total

Review 1.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

Review 2.  Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Authors:  Thomas R E Barnes; Carol Paton
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

3.  Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital.

Authors:  Ihechiluru G Anozie; Bawo O James; Joyce O Omoaregba; Sunday O Oriji; Paul O Erohubie; Anthony C Enebe
Journal:  S Afr J Psychiatr       Date:  2022-04-29       Impact factor: 1.242

Review 4.  Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Authors:  Nitin Toteja; Juan A Gallego; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; Christoph U Correll
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

Review 5.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

Review 6.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

7.  Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia.

Authors:  Yen-Li Goh; Kok Han Seng; Alex Su Hsin Chuan; Hong Choon Chua
Journal:  Perm J       Date:  2011

8.  Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.

Authors:  Sara S McMillan; Sara Jacobs; Louise Wilson; Theo Theodoros; Gail Robinson; Claire Anderson; Gabor Mihala; Amanda J Wheeler
Journal:  BMC Psychiatry       Date:  2017-04-13       Impact factor: 3.630

9.  Prevalence and correlates of "high dose" antipsychotic prescribing: findings from a hospital audit.

Authors:  Ao Adesola; Ig Anozie; P Erohubie; Bo James
Journal:  Ann Med Health Sci Res       Date:  2013-01

10.  Antipsychotic Polypharmacy Among Patients With Schizophrenia in Africa: A Systematic Review and Meta-Analysis.

Authors:  Wondim Ayenew; Getahun Asmamaw; Teshome Bitew
Journal:  Int J Neuropsychopharmacol       Date:  2021-12-08       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.